188 related articles for article (PubMed ID: 32996844)
1. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
Crapis M; Venturini S; Della Siega P; Tonizzo M; Garlatti E; Rosa R; Basso B; Pontoni E
J Chemother; 2021 May; 33(3):174-179. PubMed ID: 32996844
[TBL] [Abstract][Full Text] [Related]
2. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Syed YY
Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
[TBL] [Abstract][Full Text] [Related]
3. Ceftobiprole for the treatment of pneumonia: a European perspective.
Liapikou A; Cillóniz C; Torres A
Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
[TBL] [Abstract][Full Text] [Related]
4. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole: drug evaluation and place in therapy.
Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
[No Abstract] [Full Text] [Related]
6. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
[TBL] [Abstract][Full Text] [Related]
8. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
Falcó V; Burgos J; Almirante B
Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
[TBL] [Abstract][Full Text] [Related]
9. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
[TBL] [Abstract][Full Text] [Related]
11. Ceftobiprole for the treatment of pneumonia.
Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Torres A; Mouton JW; Pea F
Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Horn KS; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
[TBL] [Abstract][Full Text] [Related]
14. A
Huang H; Gao L; Engelhardt M; Saulay M; Hamed K
Future Microbiol; 2021 Jul; 16():783-796. PubMed ID: 34155899
[TBL] [Abstract][Full Text] [Related]
15. Are third-generation cephalosporins associated with a better prognosis than amoxicillin-clavulanate in patients hospitalized in the medical ward for community-onset pneumonia?
Batard E; Javaudin F; Kervagoret E; Caruana E; Le Bastard Q; Chapelet G; Goffinet N; Montassier E
Clin Microbiol Infect; 2018 Nov; 24(11):1171-1176. PubMed ID: 29964229
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
17. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
18. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of ceftobiprole.
Grau S
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340
[TBL] [Abstract][Full Text] [Related]
20. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
Gentile I; Buonomo AR; Corcione S; Paradiso L; Giacobbe DR; Bavaro DF; Tiseo G; Sordella F; Bartoletti M; Palmiero G; Vozza A; Vena A; Canta F; Moriello NS; Congera P; Karruli A; Tascini C; Viale P; Bono VD; Falcone M; Carbonara S; Mikulska MK; Bassetti M; Durante-Mangoni E; De Rosa FG; Maraolo AE
Int J Antimicrob Agents; 2023 Jul; 62(1):106817. PubMed ID: 37061102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
